NANO.PA · Nanobiotix S.A

-

Please sign in to comment on NANO.PA

1 Comment

Admin

4 years ago

Nanobiotix S.A is currently in a long term downtrend where the price is trading 2.2% below its 200 day moving average.

From a valuation standpoint, the stock is 1518.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 4423.3.

Nanobiotix S.A's total revenue sank by 89.7% to $37K since the same quarter in the previous year.

Its net income has dropped by 52.5% to $-21M since the same quarter in the previous year.

Finally, its free cash flow grew by 35.1% to $-6M since the same quarter in the previous year.

Based on the above factors, Nanobiotix S.A gets an overall score of 1/5.

ISIN	FR0011341205
Industry	Biotechnology
Exchange	PA
CurrencyCode	EUR
Sector	Healthcare

Market Cap	141M
PE Ratio	None
Target Price	11.1833
Beta	1.55
Dividend Yield	None

ABOUT

Nanobiotix S.A

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

NANO.PA · Nanobiotix S.A

-

Nanobiotix S.A

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Nanobiotix S.A using a moving average strategy